Shots:

• The ongoing P-III ADvocate 1 & 2 studies evaluate lebrikizumab as monothx. vs PBO in adult & adolescent patients aged 12 to less than 18 yrs. with mod. to sev. AD for 52wks.
• The 1EPs & 2EPs of study i.e >75% change from baseline in EASI score @16wks.- improvement in skin clearance & itch including QoL while safety profile was consistent with prior studies of lebrikizumab
• Lilly gets exclusive rights for the development & commercialization of lebrikizumab in the US & other countries outside the EU while Almirall gets the rights to develop and commercialize the therapy for dermatology indications including the AD in the EU. The therapy has received FTD for a mod. to sev. AD

| Ref: PR Newswire | Image: Wall Street Journal